Medpace Holdings Inc

MEDP: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$899.00ZbvmwhRxtlbjg

Medpace Holdings: Healthy Outsourcing Demand Supports Strong Growth; $227 Fair Value Estimate

We have launched coverage of Medpace, a global contract research organization, or CRO. We assign Medpace a fair value estimate of $227 per share and view the stock as fairly valued. It’s currently trading in 3-star territory. We believe Medpace has a narrow economic moat and stable moat trend based on its intangible assets and high switching costs for its customers.

Sponsor Center